| Biomarker ID | 39 |
| PMID | 12507908 |
| Year | 2003 |
| Biomarker | Annexin 2 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated in Metastatic hormone refractory PCa (1.51 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Incldue:-Prostaglandin biosynthesis and regulation,Differentiation pathway in PC12 cells |
| Experiment | Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer |
| Type of Biomarker | Prognostic |
| Cohort | 20 patients with late stage Prostate Cancer (Hormone Refactory) and 16 with early stage (Hormone Naive) and 21 non cancerous samples were chosen for the study. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.009 |
| Method Used | cDNA Microarray |
| Clinical | No |
| Remarks | Only Annexin 1 and 4 showed significant downregulation in early stage samples as compared to the benign samples. Annexins 1,2,4,6,7,8,11,13 were all tested for differential expression and 6,8,13 were not found to be differentially expressed |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | ANXA2 |